Chronic lung diseases: prospects for regeneration and repair
COPD and idiopathic pulmonary fibrosis (IPF) together represent a considerable unmet medical need, and advances in their treatment lag well behind those of other chronic conditions. Both diseases involve maladaptive repair mechanisms leading to progressive and irreversible damage. However, our under...
Saved in:
Published in | European respiratory review Vol. 30; no. 159; p. 200213 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
England
European Respiratory Society
31.03.2021
|
Subjects | |
Online Access | Get full text |
ISSN | 0905-9180 1600-0617 1600-0617 |
DOI | 10.1183/16000617.0213-2020 |
Cover
Abstract | COPD and idiopathic pulmonary fibrosis (IPF) together represent a considerable unmet medical need, and advances in their treatment lag well behind those of other chronic conditions. Both diseases involve maladaptive repair mechanisms leading to progressive and irreversible damage. However, our understanding of the complex underlying disease mechanisms is incomplete; with current diagnostic approaches, COPD and IPF are often discovered at an advanced stage and existing definitions of COPD and IPF can be misleading. To halt or reverse disease progression and achieve lung regeneration, there is a need for earlier identification and treatment of these diseases. A precision medicine approach to treatment is also important, involving the recognition of disease subtypes, or endotypes, according to underlying disease mechanisms, rather than the current “one-size-fits-all” approach. This review is based on discussions at a meeting involving 38 leading global experts in chronic lung disease mechanisms, and describes advances in the understanding of the pathology and molecular mechanisms of COPD and IPF to identify potential targets for reversing disease degeneration and promoting tissue repair and lung regeneration. We also discuss limitations of existing disease measures, technical advances in understanding disease pathology, and novel methods for targeted drug delivery. |
---|---|
AbstractList | COPD and idiopathic pulmonary fibrosis (IPF) together represent a considerable unmet medical need, and advances in their treatment lag well behind those of other chronic conditions. Both diseases involve maladaptive repair mechanisms leading to progressive and irreversible damage. However, our understanding of the complex underlying disease mechanisms is incomplete; with current diagnostic approaches, COPD and IPF are often discovered at an advanced stage and existing definitions of COPD and IPF can be misleading. To halt or reverse disease progression and achieve lung regeneration, there is a need for earlier identification and treatment of these diseases. A precision medicine approach to treatment is also important, involving the recognition of disease subtypes, or endotypes, according to underlying disease mechanisms, rather than the current “one-size-fits-all” approach. This review is based on discussions at a meeting involving 38 leading global experts in chronic lung disease mechanisms, and describes advances in the understanding of the pathology and molecular mechanisms of COPD and IPF to identify potential targets for reversing disease degeneration and promoting tissue repair and lung regeneration. We also discuss limitations of existing disease measures, technical advances in understanding disease pathology, and novel methods for targeted drug delivery. COPD and idiopathic pulmonary fibrosis (IPF) together represent a considerable unmet medical need, and advances in their treatment lag well behind those of other chronic conditions. Both diseases involve maladaptive repair mechanisms leading to progressive and irreversible damage. However, our understanding of the complex underlying disease mechanisms is incomplete; with current diagnostic approaches, COPD and IPF are often discovered at an advanced stage and existing definitions of COPD and IPF can be misleading. To halt or reverse disease progression and achieve lung regeneration, there is a need for earlier identification and treatment of these diseases. A precision medicine approach to treatment is also important, involving the recognition of disease subtypes, or endotypes, according to underlying disease mechanisms, rather than the current "one-size-fits-all" approach. This review is based on discussions at a meeting involving 38 leading global experts in chronic lung disease mechanisms, and describes advances in the understanding of the pathology and molecular mechanisms of COPD and IPF to identify potential targets for reversing disease degeneration and promoting tissue repair and lung regeneration. We also discuss limitations of existing disease measures, technical advances in understanding disease pathology, and novel methods for targeted drug delivery.COPD and idiopathic pulmonary fibrosis (IPF) together represent a considerable unmet medical need, and advances in their treatment lag well behind those of other chronic conditions. Both diseases involve maladaptive repair mechanisms leading to progressive and irreversible damage. However, our understanding of the complex underlying disease mechanisms is incomplete; with current diagnostic approaches, COPD and IPF are often discovered at an advanced stage and existing definitions of COPD and IPF can be misleading. To halt or reverse disease progression and achieve lung regeneration, there is a need for earlier identification and treatment of these diseases. A precision medicine approach to treatment is also important, involving the recognition of disease subtypes, or endotypes, according to underlying disease mechanisms, rather than the current "one-size-fits-all" approach. This review is based on discussions at a meeting involving 38 leading global experts in chronic lung disease mechanisms, and describes advances in the understanding of the pathology and molecular mechanisms of COPD and IPF to identify potential targets for reversing disease degeneration and promoting tissue repair and lung regeneration. We also discuss limitations of existing disease measures, technical advances in understanding disease pathology, and novel methods for targeted drug delivery. COPD and idiopathic pulmonary fibrosis (IPF) together represent a considerable unmet medical need, and advances in their treatment lag well behind those of other chronic conditions. Both diseases involve maladaptive repair mechanisms leading to progressive and irreversible damage. However, our understanding of the complex underlying disease mechanisms is incomplete; with current diagnostic approaches, COPD and IPF are often discovered at an advanced stage and existing definitions of COPD and IPF can be misleading. To halt or reverse disease progression and achieve lung regeneration, there is a need for earlier identification and treatment of these diseases. A precision medicine approach to treatment is also important, involving the recognition of disease subtypes, or endotypes, according to underlying disease mechanisms, rather than the current “one-size-fits-all” approach. This review is based on discussions at a meeting involving 38 leading global experts in chronic lung disease mechanisms, and describes advances in the understanding of the pathology and molecular mechanisms of COPD and IPF to identify potential targets for reversing disease degeneration and promoting tissue repair and lung regeneration. We also discuss limitations of existing disease measures, technical advances in understanding disease pathology, and novel methods for targeted drug delivery. Treatment outcomes with COPD and IPF are suboptimal. Better understanding of the diseases, such as targetable repair mechanisms, may generate novel therapies, and earlier diagnosis and treatment is needed to stop or even reverse disease progression. https://bit.ly/2Ga8J1g |
Author | Anderson, Gary P. Fagerås, Malin Belvisi, Maria G. Barnes, Peter J. |
AuthorAffiliation | 3 AstraZeneca, Gothenburg, Sweden 4 Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden 2 Lung Health Research Centre, University of Melbourne, Melbourne, Australia 1 National Heart & Lung Institute, Imperial College London, London, UK |
AuthorAffiliation_xml | – name: 2 Lung Health Research Centre, University of Melbourne, Melbourne, Australia – name: 4 Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden – name: 1 National Heart & Lung Institute, Imperial College London, London, UK – name: 3 AstraZeneca, Gothenburg, Sweden |
Author_xml | – sequence: 1 givenname: Peter J. surname: Barnes fullname: Barnes, Peter J. – sequence: 2 givenname: Gary P. surname: Anderson fullname: Anderson, Gary P. – sequence: 3 givenname: Malin surname: Fagerås fullname: Fagerås, Malin – sequence: 4 givenname: Maria G. surname: Belvisi fullname: Belvisi, Maria G. |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33408088$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kc1v1DAQxS1URLeFf4ADypFLyvgrsRFCQis-KlXiAmdrYk-2rrJxsLOV-O9Jum1FOXCy9Pzeb0bzztjJmEZi7DWHC86NfMcbAGh4ewGCy1qAgGdss4r1qp6wDVjQteUGTtlZKTcAChpoX7BTKRUYMGbDPmyvcxqjr4bDuKtCLISFyvtqyqlM5OdS9SlXmXY0UsY5prHCMSzChDG_ZM97HAq9un_P2c8vn39sv9VX379ebj9d1V41Zq47G1AFRFQieEFa6b7rEXujKRgCoY23QkofyAauTNsFj1py1UrlqbMkz9nlkRsS3rgpxz3m3y5hdHdCyjuHeY5-INej6YzXbau9UeQNWi81F6j6HqyS3cL6eGRNh25PwdM4ZxyeQJ_-jPHa7dKts8oYq_QCeHsPyOnXgcrs9rF4GgYcKR2KE6ptuGi1gsX65u9Zj0Mezr8YxNHgl3OXTP2jhYNbO3YPHbu1Y7d2vITMPyEf57tqln3j8L_oH6yLq44 |
CitedBy_id | crossref_primary_10_1007_s10753_024_02077_4 crossref_primary_10_1016_j_biopha_2021_112216 crossref_primary_10_1038_s41467_023_44184_0 crossref_primary_10_1126_sciadv_abp8322 crossref_primary_10_3390_cancers14153819 crossref_primary_10_3390_antiox11101885 crossref_primary_10_1007_s40264_024_01400_0 crossref_primary_10_3390_microorganisms12102030 crossref_primary_10_1186_s12931_022_02146_y crossref_primary_10_23736_S0026_4806_22_08024_7 crossref_primary_10_1186_s12950_022_00308_9 crossref_primary_10_1017_erm_2022_27 crossref_primary_10_1016_j_arr_2024_102294 crossref_primary_10_1016_j_jconrel_2024_05_043 |
Cites_doi | 10.1016/j.rmed.2017.07.062 10.1164/rccm.201605-0904OC 10.1378/chest.14-0373 10.1136/thoraxjnl-2013-204778 10.1371/journal.pone.0002142 10.1038/srep35871 10.1016/S0140-6736(11)60052-4 10.1183/09031936.00069712 10.1183/09031936.03.00119103 10.5966/sctm.2015-0337 10.1016/S0140-6736(06)68516-4 10.1007/s41030-015-0009-4 10.1165/rcmb.2016-0284OC 10.1164/rccm.201707-1519oc 10.1016/j.jaci.2016.08.004 10.1093/aje/152.4.307 10.1016/j.matbio.2018.01.023 10.1164/ajrccm.155.1.9001319 10.1016/S0140-6736(04)16900-6 10.1084/jem.20162152 10.1002/dvdy.10222 10.1136/bmjresp-2018-000397 10.1016/j.ajpath.2014.01.012 10.1371/journal.pgen.1003228 10.1242/dev.125.7.1315 10.1016/j.ijrobp.2017.02.216 10.1183/09031936.03.00089403 10.1056/NEJMra1705751 10.1183/16000617.0010-2019 10.1016/S0140-6736(08)61452-X 10.1378/chest.11-2348 10.1183/16000617.0122-2018 10.1016/j.rmed.2016.05.005 10.1021/acschembio.5b00216 10.1016/j.biopha.2019.108756 10.1016/j.mric.2015.01.003 10.2147/COPD.S131847 10.1038/s41467-018-07768-9 10.1164/rccm.201704-0667OC 10.1039/c2ib00149g 10.1165/rcmb.2006-0029OC 10.1016/j.rmed.2018.05.004 10.1172/jci.insight.93203 10.1146/annurev.physiol.65.092101.142446 10.3389/fmed.2018.00087 10.1136/thoraxjnl-2018-212630 10.1002/jmri.20876 10.1183/09031936.00007915 10.1152/japplphysiol.00732.2006 10.1002/mrm.26279 10.1371/journal.pone.0037483 10.1371/journal.pbio.2000731 10.1183/13993003.00026-2015 10.1164/rccm.201811-2083OC 10.1152/ajplung.00423.2015 10.1016/j.reprotox.2017.05.014 10.1001/jama.2018.13103 10.1126/scitranslmed.aal3765 10.1242/dmm.006031 10.1378/chest.130.5.1334 10.1016/S2213-2600(18)30196-6 10.1186/s12890-017-0468-5 10.1093/eurheartj/ehw272 10.1016/S2213-2600(17)30430-7 10.1016/S2213-2600(15)00283-0 10.1056/NEJMoa1106955 10.1111/crj.12147 10.1172/jci33950 10.1186/s12931-018-0717-z 10.1186/s12931-017-0699-2 10.1183/09031936.04.00014304 10.1016/j.pharmthera.2018.11.008 10.1164/rccm.201506-1063ST 10.1038/ncomms14532 10.1164/rccm.200712-1776OC 10.1183/09031936.00077309 10.1016/S2213-2600(13)70045-6 10.1164/rccm.201208-1361OC 10.1038/nrdp.2015.76 10.1172/jci.insight.123614 10.1016/S2213-2600(18)30135-8 10.12688/f1000research.7018.1 10.1164/rccm.201806-1166PP 10.1007/s12149-014-0913-y 10.1164/rccm.200910-1560OC 10.1016/S0002-9440(10)63147-1 10.1016/S2213-2600(15)00048-X 10.1016/j.rmed.2004.12.010 10.1164/rccm.201104-0597OC 10.1136/thoraxjnl-2014-206084 10.1164/rccm.201810-1975TR 10.2147/IJN.S182384 10.1172/JCI98224 10.1096/fj.201800965R 10.1164/rccm.201808-1557ED 10.1038/s41598-018-21727-w 10.1007/s40291-019-00413-1 10.1016/j.mam.2017.11.005 10.1186/1465-9921-9-52 10.1183/09059180.00000813 10.1111/all.13760 10.1016/j.chest.2018.08.1021 10.1016/j.rmed.2015.09.006 10.1016/j.ebiom.2018.12.052 10.1152/ajplung.00037.2018 10.1152/ajplung.00097.2010 10.1016/j.ejim.2019.07.005 10.1038/nm.2971 10.1038/s41598-017-02871-1 10.1038/nrd.2017.244 10.1096/fj.08-125468 10.1164/rccm.201712-2551OC 10.1056/NEJMoa1013660 10.1111/jcmm.12672 10.1634/theoncologist.2009-0042 10.1007/978-1-4939-3753-0_19 10.1513/AnnalsATS.201808-533MG 10.1136/thoraxjnl-2018-211851 10.2147/COPD.S164285 10.1136/thoraxjnl-2016-209753 10.1517/13543784.2013.778972 10.1016/j.chest.2018.07.030 10.1155/2017/3520581 10.1084/jem.20160675 10.3390/molecules22010139 10.1136/thoraxjnl-2016-208846 10.1097/MCP.0000000000000553 10.2967/jnumed.116.184796 10.1164/ajrccm.165.5.2106123 10.1159/000475780 10.1111/resp.13527 10.1183/09031936.00161911 10.1186/s12931-017-0642-6 10.18632/aging.100807 10.1016/S0140-6736(12)61144-1 10.1016/J.PHARMTHERA.2017.10.005 10.1007/s12325-018-0693-1 |
ContentType | Journal Article |
Copyright | Copyright ©ERS 2021. Copyright ©ERS 2021. 2021 |
Copyright_xml | – notice: Copyright ©ERS 2021. – notice: Copyright ©ERS 2021. 2021 |
DBID | AAYXX CITATION NPM 7X8 5PM DOA |
DOI | 10.1183/16000617.0213-2020 |
DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
DatabaseTitleList | CrossRef PubMed MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | Chronic lung diseases: regeneration and repair |
EISSN | 1600-0617 |
ExternalDocumentID | oai_doaj_org_article_fa8b8c5775c84ec8a9c3512a4ff0943b PMC9488945 33408088 10_1183_16000617_0213_2020 |
Genre | Journal Article Review |
GroupedDBID | --- 29G 2WC 5GY 5VS 6~0 6~1 AAYXX ABOCM ABSQV ACEMG ADBBV ADMOG ALMA_UNASSIGNED_HOLDINGS BAWUL BCNDV BTFSW CITATION DIK DU5 E3Z EBS EE- EJD F5P F9R GROUPED_DOAJ GX1 H13 INIJC KQ8 OK1 R0Z RHI RNS RPM TER TR2 W8F WOQ AIPOO M~E NPM RHF 7X8 5PM |
ID | FETCH-LOGICAL-c468t-b9da4daaa42dc2e545fbfaaf85ed8e0258c9233cde9d1487bdca5314734ceb9e3 |
IEDL.DBID | DOA |
ISSN | 0905-9180 1600-0617 |
IngestDate | Wed Aug 27 01:29:09 EDT 2025 Thu Aug 21 18:39:39 EDT 2025 Thu Sep 04 16:36:33 EDT 2025 Wed Feb 19 02:29:59 EST 2025 Thu Apr 24 22:57:55 EDT 2025 Wed Aug 20 07:40:31 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 159 |
Language | English |
License | Copyright ©ERS 2021. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c468t-b9da4daaa42dc2e545fbfaaf85ed8e0258c9233cde9d1487bdca5314734ceb9e3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
OpenAccessLink | https://doaj.org/article/fa8b8c5775c84ec8a9c3512a4ff0943b |
PMID | 33408088 |
PQID | 2476127540 |
PQPubID | 23479 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_fa8b8c5775c84ec8a9c3512a4ff0943b pubmedcentral_primary_oai_pubmedcentral_nih_gov_9488945 proquest_miscellaneous_2476127540 pubmed_primary_33408088 crossref_primary_10_1183_16000617_0213_2020 crossref_citationtrail_10_1183_16000617_0213_2020 |
PublicationCentury | 2000 |
PublicationDate | 2021-03-31 |
PublicationDateYYYYMMDD | 2021-03-31 |
PublicationDate_xml | – month: 03 year: 2021 text: 2021-03-31 day: 31 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | European respiratory review |
PublicationTitleAlternate | Eur Respir Rev |
PublicationYear | 2021 |
Publisher | European Respiratory Society |
Publisher_xml | – name: European Respiratory Society |
References | Liao (2024102403514714000_30.159.200213.54) 2017; 22 Moon (2024102403514714000_30.159.200213.50) 2018; 41 Lee (2024102403514714000_30.159.200213.53) 2018; 41 Huang (2024102403514714000_30.159.200213.97) 2019; 196 Skronska-Wasek (2024102403514714000_30.159.200213.119) 2017; 196 Ohno (2024102403514714000_30.159.200213.55) 2016; 1448 Weatherley (2024102403514714000_30.159.200213.65) 2018; 74 2024102403514714000_30.159.200213.85 Houssaini (2024102403514714000_30.159.200213.109) 2018; 3 2024102403514714000_30.159.200213.88 Bell (2024102403514714000_30.159.200213.76) 2018; 13 2024102403514714000_30.159.200213.84 Martinez (2024102403514714000_30.159.200213.43) 2018; 154 Spagnolo (2024102403514714000_30.159.200213.45) 2015; 1 Chan (2024102403514714000_30.159.200213.64) 2017; 77 2024102403514714000_30.159.200213.74 Roos (2024102403514714000_30.159.200213.66) 2015; 23 2024102403514714000_30.159.200213.75 2024102403514714000_30.159.200213.77 2024102403514714000_30.159.200213.71 Wells (2024102403514714000_30.159.200213.87) 2018; 3 Dressen (2024102403514714000_30.159.200213.26) 2018; 6 2024102403514714000_30.159.200213.72 Kärkkäinen (2024102403514714000_30.159.200213.24) 2017; 18 2024102403514714000_30.159.200213.78 Garudadri (2024102403514714000_30.159.200213.79) 2018; 15 Kato (2024102403514714000_30.159.200213.137) 2015; 19 Vukmirovic (2024102403514714000_30.159.200213.41) 2018; 5 Vasilescu (2024102403514714000_30.159.200213.62) 2019; 200 Drakopanagiotakis (2024102403514714000_30.159.200213.81) 2018; 68–69 Shaykhiev (2024102403514714000_30.159.200213.128) 2019; 199 2024102403514714000_30.159.200213.20 2024102403514714000_30.159.200213.21 Piersma (2024102403514714000_30.159.200213.131) 2017; 72 2024102403514714000_30.159.200213.22 Selman (2024102403514714000_30.159.200213.38) 2018; 199 2024102403514714000_30.159.200213.28 Barnes (2024102403514714000_30.159.200213.4) 2015; 1 2024102403514714000_30.159.200213.29 Chen (2024102403514714000_30.159.200213.73) 2015; 109 2024102403514714000_30.159.200213.8 2024102403514714000_30.159.200213.23 Yanai (2024102403514714000_30.159.200213.112) 2015; 7 2024102403514714000_30.159.200213.25 2024102403514714000_30.159.200213.9 Obeidat (2024102403514714000_30.159.200213.93) 2017; 57 Cantor (2024102403514714000_30.159.200213.96) 2019; 155 2024102403514714000_30.159.200213.6 Johns (2024102403514714000_30.159.200213.10) 2014; 6 2024102403514714000_30.159.200213.5 2024102403514714000_30.159.200213.2 2024102403514714000_30.159.200213.1 Strongman (2024102403514714000_30.159.200213.3) 2018; 35 Burkes (2024102403514714000_30.159.200213.57) 2019; 25 Sauleda (2024102403514714000_30.159.200213.89) 2018; 6 Jenkins (2024102403514714000_30.159.200213.90) 2015; 3 2024102403514714000_30.159.200213.146 2024102403514714000_30.159.200213.147 Hess (2024102403514714000_30.159.200213.44) 2016; 3 2024102403514714000_30.159.200213.98 Tsantikos (2024102403514714000_30.159.200213.101) 2018; 128 2024102403514714000_30.159.200213.148 2024102403514714000_30.159.200213.11 2024102403514714000_30.159.200213.149 2024102403514714000_30.159.200213.92 Barnes (2024102403514714000_30.159.200213.105) 2019; 200 2024102403514714000_30.159.200213.143 Zhang (2024102403514714000_30.159.200213.49) 2019; 113 2024102403514714000_30.159.200213.94 2024102403514714000_30.159.200213.144 2024102403514714000_30.159.200213.95 2024102403514714000_30.159.200213.16 2024102403514714000_30.159.200213.17 2024102403514714000_30.159.200213.18 2024102403514714000_30.159.200213.140 Calvi (2024102403514714000_30.159.200213.139) 2013; 9 2024102403514714000_30.159.200213.141 2024102403514714000_30.159.200213.13 Moses (2024102403514714000_30.159.200213.52) 2019; 24 Fuschillo (2024102403514714000_30.159.200213.80) 2019; 68 2024102403514714000_30.159.200213.129 2024102403514714000_30.159.200213.135 2024102403514714000_30.159.200213.42 Pisi (2024102403514714000_30.159.200213.70) 2015; 10 2024102403514714000_30.159.200213.138 Fawzy (2024102403514714000_30.159.200213.86) 2018; 19 2024102403514714000_30.159.200213.132 2024102403514714000_30.159.200213.133 2024102403514714000_30.159.200213.134 Cazzola (2024102403514714000_30.159.200213.82) 2019; 23 Noth (2024102403514714000_30.159.200213.19) 2013; 1 2024102403514714000_30.159.200213.130 2024102403514714000_30.159.200213.46 2024102403514714000_30.159.200213.47 2024102403514714000_30.159.200213.48 Barnes (2024102403514714000_30.159.200213.40) 2019; 74 Naseri (2024102403514714000_30.159.200213.56) 2018; 13 Wang (2024102403514714000_30.159.200213.15) 2015; 9 Lowe (2024102403514714000_30.159.200213.60) 2019; 6 2024102403514714000_30.159.200213.117 2024102403514714000_30.159.200213.118 Ohmichi (2024102403514714000_30.159.200213.136) 1998; 125 2024102403514714000_30.159.200213.30 2024102403514714000_30.159.200213.124 2024102403514714000_30.159.200213.31 2024102403514714000_30.159.200213.32 2024102403514714000_30.159.200213.127 2024102403514714000_30.159.200213.120 2024102403514714000_30.159.200213.121 2024102403514714000_30.159.200213.123 2024102403514714000_30.159.200213.39 2024102403514714000_30.159.200213.34 2024102403514714000_30.159.200213.35 2024102403514714000_30.159.200213.36 2024102403514714000_30.159.200213.37 Pan (2024102403514714000_30.159.200213.99) 2017; 99 Lipworth (2024102403514714000_30.159.200213.58) 2018; 139 Bajc (2024102403514714000_30.159.200213.67) 2017; 12 Hoff (2024102403514714000_30.159.200213.61) 2017; 7 2024102403514714000_30.159.200213.107 Shi (2024102403514714000_30.159.200213.122) 2017; 2017 2024102403514714000_30.159.200213.63 2024102403514714000_30.159.200213.113 Anderson (2024102403514714000_30.159.200213.14) 2016; 5 2024102403514714000_30.159.200213.114 Maher (2024102403514714000_30.159.200213.91) 2017; 5 2024102403514714000_30.159.200213.116 Kadota (2024102403514714000_30.159.200213.110) 2018; 60 2024102403514714000_30.159.200213.111 Magnini (2024102403514714000_30.159.200213.83) 2017; 93 Balestrini (2024102403514714000_30.159.200213.145) 2012; 4 2024102403514714000_30.159.200213.68 2024102403514714000_30.159.200213.69 Ghosh (2024102403514714000_30.159.200213.125) 2018; 197 Maher (2024102403514714000_30.159.200213.33) 2017; 17 Weeden (2024102403514714000_30.159.200213.126) 2017; 15 Papaioannou (2024102403514714000_30.159.200213.27) 2016; 117 Baker (2024102403514714000_30.159.200213.108) 2019; 33 2024102403514714000_30.159.200213.102 2024102403514714000_30.159.200213.103 Wain (2024102403514714000_30.159.200213.12) 2015; 3 2024102403514714000_30.159.200213.104 Chakraborty (2024102403514714000_30.159.200213.142) 2013; 22 2024102403514714000_30.159.200213.100 2024102403514714000_30.159.200213.51 Baker (2024102403514714000_30.159.200213.106) 2016; 6 Koo (2024102403514714000_30.159.200213.7) 2018; 6 Justice (2024102403514714000_30.159.200213.115) 2019; 40 2024102403514714000_30.159.200213.59 |
References_xml | – ident: 2024102403514714000_30.159.200213.32 doi: 10.1016/j.rmed.2017.07.062 – volume: 196 start-page: 172 year: 2017 ident: 2024102403514714000_30.159.200213.119 article-title: Reduced frizzled receptor 4 expression prevents WNT/β-catenin-driven alveolar lung repair in chronic obstructive pulmonary disease publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.201605-0904OC – ident: 2024102403514714000_30.159.200213.141 doi: 10.1378/chest.14-0373 – ident: 2024102403514714000_30.159.200213.85 doi: 10.1136/thoraxjnl-2013-204778 – ident: 2024102403514714000_30.159.200213.120 doi: 10.1371/journal.pone.0002142 – volume: 6 start-page: 35871 year: 2016 ident: 2024102403514714000_30.159.200213.106 article-title: Oxidative stress dependent microRNA-34a activation via PI3Kalpha reduces the expression of sirtuin-1 and sirtuin-6 in epithelial cells publication-title: Sci Rep doi: 10.1038/srep35871 – volume: 41 start-page: 933 year: 2018 ident: 2024102403514714000_30.159.200213.50 article-title: Chemically induced cellular proteolysis: an emerging therapeutic strategy for undruggable targets publication-title: Mol Cells – ident: 2024102403514714000_30.159.200213.21 doi: 10.1016/S0140-6736(11)60052-4 – ident: 2024102403514714000_30.159.200213.74 doi: 10.1183/09031936.00069712 – ident: 2024102403514714000_30.159.200213.47 doi: 10.1183/09031936.03.00119103 – ident: 2024102403514714000_30.159.200213.140 doi: 10.5966/sctm.2015-0337 – ident: 2024102403514714000_30.159.200213.11 doi: 10.1016/S0140-6736(06)68516-4 – volume: 1 start-page: 1 year: 2015 ident: 2024102403514714000_30.159.200213.45 article-title: Current and future therapies for idiopathic pulmonary fibrosis publication-title: Pulm Ther doi: 10.1007/s41030-015-0009-4 – ident: 2024102403514714000_30.159.200213.1 – volume: 57 start-page: 411 year: 2017 ident: 2024102403514714000_30.159.200213.93 article-title: Integrative genomics of emphysema-associated genes reveals potential disease biomarkers publication-title: Am J Respir Cell Mol Biol doi: 10.1165/rcmb.2016-0284OC – ident: 2024102403514714000_30.159.200213.143 doi: 10.1164/rccm.201707-1519oc – ident: 2024102403514714000_30.159.200213.77 doi: 10.1016/j.jaci.2016.08.004 – ident: 2024102403514714000_30.159.200213.149 doi: 10.1093/aje/152.4.307 – volume: 68–69 start-page: 404 year: 2018 ident: 2024102403514714000_30.159.200213.81 article-title: Biomarkers in idiopathic pulmonary fibrosis publication-title: Matrix Biol doi: 10.1016/j.matbio.2018.01.023 – ident: 2024102403514714000_30.159.200213.23 doi: 10.1164/ajrccm.155.1.9001319 – ident: 2024102403514714000_30.159.200213.5 doi: 10.1016/S0140-6736(04)16900-6 – ident: 2024102403514714000_30.159.200213.20 doi: 10.1084/jem.20162152 – ident: 2024102403514714000_30.159.200213.130 doi: 10.1002/dvdy.10222 – ident: 2024102403514714000_30.159.200213.35 doi: 10.1136/bmjresp-2018-000397 – volume: 6 start-page: 384 year: 2019 ident: 2024102403514714000_30.159.200213.60 article-title: COPDGene® 2019: redefining the diagnosis of chronic obstructive pulmonary disease publication-title: Chronic Obstr Pulm Dis – ident: 2024102403514714000_30.159.200213.129 doi: 10.1016/j.ajpath.2014.01.012 – volume: 9 start-page: e1003228 year: 2013 ident: 2024102403514714000_30.159.200213.139 article-title: Hepatocyte growth factor, a determinant of airspace homeostasis in the murine lung publication-title: PLoS Genet doi: 10.1371/journal.pgen.1003228 – volume: 125 start-page: 1315 year: 1998 ident: 2024102403514714000_30.159.200213.136 article-title: Hepatocyte growth factor (HGF) acts as a mesenchyme-derived morphogenic factor during fetal lung development publication-title: Development doi: 10.1242/dev.125.7.1315 – volume: 99 start-page: 353 year: 2017 ident: 2024102403514714000_30.159.200213.99 article-title: Inhibition of Bcl-2/xl with ABT-263 selectively kills senescent type II pneumocytes and reverses persistent pulmonary fibrosis induced by ionizing radiation in mice publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2017.02.216 – ident: 2024102403514714000_30.159.200213.71 doi: 10.1183/09031936.03.00089403 – ident: 2024102403514714000_30.159.200213.18 doi: 10.1056/NEJMra1705751 – ident: 2024102403514714000_30.159.200213.9 doi: 10.1183/16000617.0010-2019 – volume: 6 start-page: 1557 year: 2014 ident: 2024102403514714000_30.159.200213.10 article-title: Diagnosis and early detection of COPD using spirometry publication-title: J Thorac Dis – ident: 2024102403514714000_30.159.200213.39 doi: 10.1016/S0140-6736(08)61452-X – ident: 2024102403514714000_30.159.200213.16 doi: 10.1378/chest.11-2348 – ident: 2024102403514714000_30.159.200213.75 doi: 10.1183/16000617.0122-2018 – volume: 117 start-page: 14 year: 2016 ident: 2024102403514714000_30.159.200213.27 article-title: Combined pulmonary fibrosis and emphysema: the many aspects of a cohabitation contract publication-title: Respir Med doi: 10.1016/j.rmed.2016.05.005 – ident: 2024102403514714000_30.159.200213.51 doi: 10.1021/acschembio.5b00216 – volume: 113 start-page: 108756 year: 2019 ident: 2024102403514714000_30.159.200213.49 article-title: Interleukin-18 promotes fibroblast senescence in pulmonary fibrosis through down-regulating Klotho expression publication-title: Biomed Pharmacother doi: 10.1016/j.biopha.2019.108756 – volume: 23 start-page: 217 year: 2015 ident: 2024102403514714000_30.159.200213.66 article-title: Hyperpolarized gas MR imaging: technique and applications publication-title: Magn Reson Imaging Clin N Am doi: 10.1016/j.mric.2015.01.003 – volume: 12 start-page: 1579 year: 2017 ident: 2024102403514714000_30.159.200213.67 article-title: Identifying the heterogeneity of COPD by V/P SPECT: a new tool for improving the diagnosis of parenchymal defects and grading the severity of small airways disease publication-title: Int J Chron Obstruct Pulmon Dis doi: 10.2147/COPD.S131847 – ident: 2024102403514714000_30.159.200213.92 doi: 10.1038/s41467-018-07768-9 – volume: 197 start-page: 885 year: 2018 ident: 2024102403514714000_30.159.200213.125 article-title: Exhaustion of airway basal progenitor cells in early and established chronic obstructive pulmonary disease publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.201704-0667OC – volume: 4 start-page: 410 year: 2012 ident: 2024102403514714000_30.159.200213.145 article-title: The mechanical memory of lung myofibroblasts publication-title: Integr Biol (Camb) doi: 10.1039/c2ib00149g – ident: 2024102403514714000_30.159.200213.48 doi: 10.1165/rcmb.2006-0029OC – volume: 139 start-page: 106 year: 2018 ident: 2024102403514714000_30.159.200213.58 article-title: What can we learn about COPD from impulse oscillometry? publication-title: Respir Med doi: 10.1016/j.rmed.2018.05.004 – volume: 3 start-page: e93203 year: 2018 ident: 2024102403514714000_30.159.200213.109 article-title: mTOR pathway activation drives lung cell senescence and emphysema publication-title: JCI Insight doi: 10.1172/jci.insight.93203 – ident: 2024102403514714000_30.159.200213.117 doi: 10.1146/annurev.physiol.65.092101.142446 – volume: 5 start-page: 87 year: 2018 ident: 2024102403514714000_30.159.200213.41 article-title: Impact of transcriptomics on our understanding of pulmonary fibrosis publication-title: Front Med (Lausanne) doi: 10.3389/fmed.2018.00087 – ident: 2024102403514714000_30.159.200213.46 doi: 10.1136/thoraxjnl-2018-212630 – ident: 2024102403514714000_30.159.200213.59 doi: 10.1002/jmri.20876 – ident: 2024102403514714000_30.159.200213.146 doi: 10.1183/09031936.00007915 – ident: 2024102403514714000_30.159.200213.68 doi: 10.1152/japplphysiol.00732.2006 – ident: 2024102403514714000_30.159.200213.37 – volume: 77 start-page: 1916 year: 2017 ident: 2024102403514714000_30.159.200213.64 article-title: Whole lung morphometry with 3D multiple b-value hyperpolarized gas MRI and compressed sensing publication-title: Magn Reson Med doi: 10.1002/mrm.26279 – ident: 2024102403514714000_30.159.200213.88 doi: 10.1371/journal.pone.0037483 – volume: 15 start-page: e2000731 year: 2017 ident: 2024102403514714000_30.159.200213.126 article-title: Lung basal stem cells rapidly repair DNA damage using the error-prone nonhomologous end-joining pathway publication-title: PLoS Biol doi: 10.1371/journal.pbio.2000731 – ident: 2024102403514714000_30.159.200213.34 doi: 10.1183/13993003.00026-2015 – volume: 200 start-page: 575 year: 2019 ident: 2024102403514714000_30.159.200213.62 article-title: Non-invasive imaging biomarker identifies small airway damage in severe COPD publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.201811-2083OC – ident: 2024102403514714000_30.159.200213.138 doi: 10.1152/ajplung.00423.2015 – volume: 72 start-page: 53 year: 2017 ident: 2024102403514714000_30.159.200213.131 article-title: Retinoic acid in developmental toxicology: teratogen, morphogen and biomarker publication-title: Reprod Toxicol doi: 10.1016/j.reprotox.2017.05.014 – ident: 2024102403514714000_30.159.200213.31 doi: 10.1001/jama.2018.13103 – ident: 2024102403514714000_30.159.200213.100 doi: 10.1126/scitranslmed.aal3765 – ident: 2024102403514714000_30.159.200213.123 doi: 10.1242/dmm.006031 – ident: 2024102403514714000_30.159.200213.135 doi: 10.1378/chest.130.5.1334 – volume: 6 start-page: 591 year: 2018 ident: 2024102403514714000_30.159.200213.7 article-title: Small airways disease in mild and moderate chronic obstructive pulmonary disease: a cross-sectional study publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(18)30196-6 – volume: 17 start-page: 124 year: 2017 ident: 2024102403514714000_30.159.200213.33 article-title: Unmet needs in the treatment of idiopathic pulmonary fibrosis – insights from patient chart review in five European countries publication-title: BMC Pulm Med doi: 10.1186/s12890-017-0468-5 – ident: 2024102403514714000_30.159.200213.95 doi: 10.1093/eurheartj/ehw272 – volume: 5 start-page: 946 year: 2017 ident: 2024102403514714000_30.159.200213.91 article-title: An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(17)30430-7 – volume: 3 start-page: 473 year: 2016 ident: 2024102403514714000_30.159.200213.44 article-title: Back to the future: past, present, and future is COPD360 publication-title: Chronic Obstr Pulm Dis – volume: 3 start-page: 769 year: 2015 ident: 2024102403514714000_30.159.200213.12 article-title: Novel insights into the genetics of smoking behaviour, lung function, and chronic obstructive pulmonary disease (UK BiLEVE): a genetic association study in UK Biobank publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(15)00283-0 – ident: 2024102403514714000_30.159.200213.6 doi: 10.1056/NEJMoa1106955 – volume: 9 start-page: 330 year: 2015 ident: 2024102403514714000_30.159.200213.15 article-title: Imbalance of peripheral blood Th17 and Treg responses in patients with chronic obstructive pulmonary disease publication-title: Clin Respir J doi: 10.1111/crj.12147 – ident: 2024102403514714000_30.159.200213.121 doi: 10.1172/jci33950 – volume: 19 start-page: 20 year: 2018 ident: 2024102403514714000_30.159.200213.86 article-title: Association of thrombocytosis with COPD morbidity: the SPIROMICS and COPDGene cohorts publication-title: Respir Res doi: 10.1186/s12931-018-0717-z – ident: 2024102403514714000_30.159.200213.94 doi: 10.1186/s12931-017-0699-2 – ident: 2024102403514714000_30.159.200213.42 doi: 10.1183/09031936.04.00014304 – volume: 196 start-page: 79 year: 2019 ident: 2024102403514714000_30.159.200213.97 article-title: Activating Wnt/β-catenin signaling pathway for disease therapy: challenges and opportunities publication-title: Pharmacol Ther doi: 10.1016/j.pharmthera.2018.11.008 – ident: 2024102403514714000_30.159.200213.17 doi: 10.1164/rccm.201506-1063ST – ident: 2024102403514714000_30.159.200213.114 doi: 10.1038/ncomms14532 – ident: 2024102403514714000_30.159.200213.72 doi: 10.1164/rccm.200712-1776OC – ident: 2024102403514714000_30.159.200213.2 doi: 10.1183/09031936.00077309 – volume: 1 start-page: 309 year: 2013 ident: 2024102403514714000_30.159.200213.19 article-title: Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(13)70045-6 – ident: 2024102403514714000_30.159.200213.111 doi: 10.1164/rccm.201208-1361OC – volume: 1 start-page: 15076 year: 2015 ident: 2024102403514714000_30.159.200213.4 article-title: Chronic obstructive pulmonary disease publication-title: Nat Rev Dis Primers doi: 10.1038/nrdp.2015.76 – volume: 3 start-page: e123614 year: 2018 ident: 2024102403514714000_30.159.200213.87 article-title: Elevated circulating MMP-9 is linked to increased COPD exacerbation risk in SPIROMICS and COPDGene publication-title: JCI Insight doi: 10.1172/jci.insight.123614 – volume: 6 start-page: 603 year: 2018 ident: 2024102403514714000_30.159.200213.26 article-title: Analysis of protein-altering variants in telomerase genes and their association with MUC5B common variant status in patients with idiopathic pulmonary fibrosis: a candidate gene sequencing study publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(18)30135-8 – volume: 5 start-page: 2392 year: 2016 ident: 2024102403514714000_30.159.200213.14 article-title: Advances in understanding COPD publication-title: F1000Res doi: 10.12688/f1000research.7018.1 – volume: 41 start-page: 943 year: 2018 ident: 2024102403514714000_30.159.200213.53 article-title: CRISPR and target-specific DNA endonucleases for efficient DNA knock-in in eukaryotic genomes publication-title: Mol Cells – volume: 199 start-page: 279 year: 2018 ident: 2024102403514714000_30.159.200213.38 article-title: Why does an aging smoker's lung develop idiopathic pulmonary fibrosis and not chronic obstructive pulmonary disease? publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.201806-1166PP – ident: 2024102403514714000_30.159.200213.69 doi: 10.1007/s12149-014-0913-y – ident: 2024102403514714000_30.159.200213.98 doi: 10.1164/rccm.200910-1560OC – ident: 2024102403514714000_30.159.200213.124 doi: 10.1016/S0002-9440(10)63147-1 – volume: 3 start-page: 462 year: 2015 ident: 2024102403514714000_30.159.200213.90 article-title: Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(15)00048-X – ident: 2024102403514714000_30.159.200213.28 doi: 10.1016/j.rmed.2004.12.010 – ident: 2024102403514714000_30.159.200213.78 doi: 10.1164/rccm.201104-0597OC – ident: 2024102403514714000_30.159.200213.102 doi: 10.1136/thoraxjnl-2014-206084 – volume: 200 start-page: 556 year: 2019 ident: 2024102403514714000_30.159.200213.105 article-title: Cellular senescence as a mechanism and target in chronic lung diseases publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.201810-1975TR – volume: 13 start-page: 7727 year: 2018 ident: 2024102403514714000_30.159.200213.56 article-title: Exosome-mediated delivery of functionally active miRNA-142-3p inhibitor reduces tumorigenicity of breast cancer in vitro and in vivo publication-title: Int J Nanomedicine doi: 10.2147/IJN.S182384 – volume: 128 start-page: 2406 year: 2018 ident: 2024102403514714000_30.159.200213.101 article-title: Granulocyte-CSF links destructive inflammation and comorbidities in obstructive lung disease publication-title: J Clin Invest doi: 10.1172/JCI98224 – volume: 33 start-page: 1605 year: 2019 ident: 2024102403514714000_30.159.200213.108 article-title: MicroRNA-570 is a novel regulator of cellular senescence and inflammaging publication-title: FASEB J doi: 10.1096/fj.201800965R – ident: 2024102403514714000_30.159.200213.36 – volume: 199 start-page: 555 year: 2019 ident: 2024102403514714000_30.159.200213.128 article-title: Basal-like cells in the BAL fluid: an Echo of regenerative crisis in idiopathic pulmonary fibrosis lungs publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.201808-1557ED – ident: 2024102403514714000_30.159.200213.144 doi: 10.1038/s41598-018-21727-w – volume: 23 start-page: 603 year: 2019 ident: 2024102403514714000_30.159.200213.82 article-title: Evolving concepts in chronic obstructive pulmonary disease blood-based biomarkers publication-title: Mol Diagn Ther doi: 10.1007/s40291-019-00413-1 – volume: 60 start-page: 92 year: 2018 ident: 2024102403514714000_30.159.200213.110 article-title: Emerging role of extracellular vesicles as a senescence-associated secretory phenotype: insights into the pathophysiology of lung diseases publication-title: Mol Aspects Med doi: 10.1016/j.mam.2017.11.005 – ident: 2024102403514714000_30.159.200213.13 doi: 10.1186/1465-9921-9-52 – ident: 2024102403514714000_30.159.200213.29 doi: 10.1183/09059180.00000813 – volume: 74 start-page: 1249 year: 2019 ident: 2024102403514714000_30.159.200213.40 article-title: Inflammatory endotypes in COPD publication-title: Allergy doi: 10.1111/all.13760 – volume: 154 start-page: 978 year: 2018 ident: 2024102403514714000_30.159.200213.43 article-title: Focus on idiopathic pulmonary fibrosis: advancing approaches to diagnosis, prognosis, and treatment publication-title: Chest doi: 10.1016/j.chest.2018.08.1021 – volume: 109 start-page: 1446 year: 2015 ident: 2024102403514714000_30.159.200213.73 article-title: Validation of human small airway measurements using endobronchial optical coherence tomography publication-title: Respir Med doi: 10.1016/j.rmed.2015.09.006 – volume: 40 start-page: 554 year: 2019 ident: 2024102403514714000_30.159.200213.115 article-title: Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study publication-title: EBioMed doi: 10.1016/j.ebiom.2018.12.052 – volume: 10 start-page: 1191 year: 2015 ident: 2024102403514714000_30.159.200213.70 article-title: Small airway dysfunction and flow and volume bronchodilator responsiveness in patients with chronic obstructive pulmonary disease publication-title: Int J Chron Obstruct Pulmon Dis – volume: 6 start-page: 110 year: 2018 ident: 2024102403514714000_30.159.200213.89 article-title: Idiopathic pulmonary fibrosis: epidemiology, natural history, phenotypes publication-title: Med Sci – ident: 2024102403514714000_30.159.200213.104 doi: 10.1152/ajplung.00037.2018 – ident: 2024102403514714000_30.159.200213.113 doi: 10.1152/ajplung.00097.2010 – volume: 68 start-page: 1 year: 2019 ident: 2024102403514714000_30.159.200213.80 article-title: Blood eosinophils as biomarkers of therapeutic response to chronic obstructive pulmonary disease: still work in progress publication-title: Eur J Intern Med doi: 10.1016/j.ejim.2019.07.005 – ident: 2024102403514714000_30.159.200213.8 doi: 10.1038/nm.2971 – ident: 2024102403514714000_30.159.200213.148 – volume: 7 start-page: 2999 year: 2017 ident: 2024102403514714000_30.159.200213.61 article-title: CT-based local distribution metric improves characterization of COPD publication-title: Sci Rep doi: 10.1038/s41598-017-02871-1 – ident: 2024102403514714000_30.159.200213.147 doi: 10.1038/nrd.2017.244 – ident: 2024102403514714000_30.159.200213.107 doi: 10.1096/fj.08-125468 – ident: 2024102403514714000_30.159.200213.127 doi: 10.1164/rccm.201712-2551OC – ident: 2024102403514714000_30.159.200213.25 doi: 10.1056/NEJMoa1013660 – volume: 19 start-page: 2818 year: 2015 ident: 2024102403514714000_30.159.200213.137 article-title: Bronchioalveolar morphogenesis of human bronchial epithelial cells depending upon hepatocyte growth factor publication-title: J Cell Mol Med doi: 10.1111/jcmm.12672 – ident: 2024102403514714000_30.159.200213.84 doi: 10.1634/theoncologist.2009-0042 – volume: 1448 start-page: 261 year: 2016 ident: 2024102403514714000_30.159.200213.55 article-title: Exosome-mediated targeted delivery of miRNAs publication-title: Methods Mol Biol doi: 10.1007/978-1-4939-3753-0_19 – volume: 15 start-page: S234 year: 2018 ident: 2024102403514714000_30.159.200213.79 article-title: Targeting chronic obstructive pulmonary disease phenotypes, endotypes, and biomarkers publication-title: Ann Am Thorac Soc doi: 10.1513/AnnalsATS.201808-533MG – volume: 74 start-page: 500 year: 2018 ident: 2024102403514714000_30.159.200213.65 article-title: Hyperpolarised xenon magnetic resonance spectroscopy for the longitudinal assessment of changes in gas diffusion in IPF publication-title: Thorax doi: 10.1136/thoraxjnl-2018-211851 – volume: 13 start-page: 2113 year: 2018 ident: 2024102403514714000_30.159.200213.76 article-title: Feasibility and challenges of using multiple breath washout in COPD publication-title: Int J Chron Obstruct Pulmon Dis doi: 10.2147/COPD.S164285 – ident: 2024102403514714000_30.159.200213.116 doi: 10.1136/thoraxjnl-2016-209753 – volume: 22 start-page: 499 year: 2013 ident: 2024102403514714000_30.159.200213.142 article-title: Hepatocyte growth factor is an attractive target for the treatment of pulmonary fibrosis publication-title: Expert Opin Investig Drugs doi: 10.1517/13543784.2013.778972 – volume: 155 start-page: 266 year: 2019 ident: 2024102403514714000_30.159.200213.96 article-title: COPD pathogenesis: finding the common in the complex publication-title: Chest doi: 10.1016/j.chest.2018.07.030 – volume: 2017 start-page: 3520581 year: 2017 ident: 2024102403514714000_30.159.200213.122 article-title: Distinct roles of WNT/beta-catenin signaling in the pathogenesis of chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis publication-title: Mediators Inflamm doi: 10.1155/2017/3520581 – ident: 2024102403514714000_30.159.200213.118 doi: 10.1084/jem.20160675 – volume: 22 start-page: E139 year: 2017 ident: 2024102403514714000_30.159.200213.54 article-title: Oligonucleotide therapy for obstructive and restrictive respiratory diseases publication-title: Molecules doi: 10.3390/molecules22010139 – ident: 2024102403514714000_30.159.200213.132 doi: 10.1136/thoraxjnl-2016-208846 – volume: 25 start-page: 132 year: 2019 ident: 2024102403514714000_30.159.200213.57 article-title: Initiating drug therapy in early stage chronic obstructive pulmonary disease: does it impact the course and outcome? publication-title: Curr Opin Pulm Med doi: 10.1097/MCP.0000000000000553 – ident: 2024102403514714000_30.159.200213.63 doi: 10.2967/jnumed.116.184796 – ident: 2024102403514714000_30.159.200213.134 doi: 10.1164/ajrccm.165.5.2106123 – volume: 93 start-page: 379 year: 2017 ident: 2024102403514714000_30.159.200213.83 article-title: Idiopathic pulmonary fibrosis: molecular endotypes of fibrosis stratifying existing and emerging therapies publication-title: Respiration doi: 10.1159/000475780 – volume: 24 start-page: 628 year: 2019 ident: 2024102403514714000_30.159.200213.52 article-title: Applications of CRISPR systems in respiratory health: entering a new “red pen” era in genome editing publication-title: Respirology doi: 10.1111/resp.13527 – ident: 2024102403514714000_30.159.200213.30 – ident: 2024102403514714000_30.159.200213.133 doi: 10.1183/09031936.00161911 – volume: 18 start-page: 160 year: 2017 ident: 2024102403514714000_30.159.200213.24 article-title: Effect of smoking and comorbidities on survival in idiopathic pulmonary fibrosis publication-title: Respir Res doi: 10.1186/s12931-017-0642-6 – volume: 7 start-page: 664 year: 2015 ident: 2024102403514714000_30.159.200213.112 article-title: Cellular senescence-like features of lung fibroblasts derived from idiopathic pulmonary fibrosis patients publication-title: Aging (Albany NY) doi: 10.18632/aging.100807 – ident: 2024102403514714000_30.159.200213.22 doi: 10.1016/S0140-6736(12)61144-1 – ident: 2024102403514714000_30.159.200213.103 doi: 10.1016/J.PHARMTHERA.2017.10.005 – volume: 35 start-page: 724 year: 2018 ident: 2024102403514714000_30.159.200213.3 article-title: Incidence, prevalence, and survival of patients with idiopathic pulmonary fibrosis in the UK publication-title: Adv Ther doi: 10.1007/s12325-018-0693-1 |
SSID | ssj0040607 |
Score | 2.3350227 |
SecondaryResourceType | review_article |
Snippet | COPD and idiopathic pulmonary fibrosis (IPF) together represent a considerable unmet medical need, and advances in their treatment lag well behind those of... |
SourceID | doaj pubmedcentral proquest pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 200213 |
SubjectTerms | Reviews |
Title | Chronic lung diseases: prospects for regeneration and repair |
URI | https://www.ncbi.nlm.nih.gov/pubmed/33408088 https://www.proquest.com/docview/2476127540 https://pubmed.ncbi.nlm.nih.gov/PMC9488945 https://doaj.org/article/fa8b8c5775c84ec8a9c3512a4ff0943b |
Volume | 30 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1600-0617 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0040607 issn: 0905-9180 databaseCode: KQ8 dateStart: 20050101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1600-0617 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0040607 issn: 0905-9180 databaseCode: DOA dateStart: 20130101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1600-0617 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0040607 issn: 0905-9180 databaseCode: DIK dateStart: 20050101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1600-0617 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0040607 issn: 0905-9180 databaseCode: GX1 dateStart: 20050101 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 1600-0617 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0040607 issn: 0905-9180 databaseCode: RPM dateStart: 20100101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LS8QwEA7iQbyIb9cXFbxJ3bZJmkS8qPhA0JMLewt5qiBVdtf_7yRpl10RvXjpoU1JmEe-CZn5BqHjmgMqwh6QW4J1Tqgrcq4YzrWhXrCSGh_ruB8e67sBuR_S4Uyrr5ATluiBk-D6XnHNDWWMGk6c4UoYDCCliPchKU6H3RdgrDtMpT0YUCoVSosidCLkRVcuw3G_rBNunwK6YTCS0Ol7BpIic_9P4eb3rMkZGLpZRStt_JhdpHWvoQXXrKOlh_aGfAOdt2y32Rt4cdZev4zPMpgoFlWOM4hSs5F7jnTTQSuZaiy8-FCvo000uLl-urrL2w4JuSE1n-RaWEWsUopU1lQOoiGvvVKeU2e5g3CGGwjgsLFOWDj3MG2NAqcjDBPjtHB4Cy02743bQVkVaHmEKXSlPAHQ1p7Vmuo6uGhBDOuhshOSNC19eOhi8SbjMYJj2QlWBsHKINgeOpn-85HIM34dfRlkPx0ZiK_jCzAH2ZqD_Msceuio05wERwm3H6px759jWRFWBzZ7AhNtJ01Op8KYQOTMeQ-xOR3PrWX-S_P6Esm4BeyAgtDd_1j8HlquQspMLHncR4uT0ac7gJhnog-jecPzdlh-Acqz_Dc |
linkProvider | Directory of Open Access Journals |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Chronic+lung+diseases%3A+prospects+for+regeneration+and+repair&rft.jtitle=European+respiratory+review&rft.au=Barnes%2C+Peter+J.&rft.au=Anderson%2C+Gary+P.&rft.au=Fager%C3%A5s%2C+Malin&rft.au=Belvisi%2C+Maria+G.&rft.date=2021-03-31&rft.issn=0905-9180&rft.eissn=1600-0617&rft.volume=30&rft.issue=159&rft.spage=200213&rft_id=info:doi/10.1183%2F16000617.0213-2020&rft.externalDBID=n%2Fa&rft.externalDocID=10_1183_16000617_0213_2020 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0905-9180&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0905-9180&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0905-9180&client=summon |